Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in First-Line Recurrent/Metastatic HNSCC
NCT02358031Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2015
- Primary completion
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Merck & Co. Primary endpoints: Progression Free Survival up to 47 months and Overall Survival up to 47 months. Started Mar 2015; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02358031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02358031.